1 The most common serious
adverse events were anaemia (eight [4%]), upper gastrointesti
2 Adverse events were attributable to 23 (5%) deaths in the doc
3 Adverse events were common with medications but not with CBT
4 The most common grade 3
adverse events were decreased lymphocyte (n=3) and decreased
5 The most common grade 3-4
adverse events were decreased neutrophil count (210 [37%] in
6 Adverse events were defined as fatal or nonfatal aortic ruptu
7 ontrol group, the most frequently reported grade 3 or worse
adverse events were diarrhoea (103 [21%] of 488 patients) fol
8 Serious
adverse events were experienced by 35 (18%) patients in the o
9 Grade 3/4
adverse events were experienced by 43% of patients.
10 The most common
adverse events were fatigue (seven participants [27%]), nasop
11 Treatment-related
adverse events were generally grade 1 or 2 in severity.
12 Adverse events were generally mild (</= grade 2), with diarrh
13 Thirteen serious
adverse events were identified among recipients of HRV, but n
14 The most common
adverse events were infective pulmonary exacerbations, cough,
15 The most common isatuximab-related
adverse events were infusion-associated reactions (IARs) (56%
16 Data on
adverse events were limited, but suggested an increased risk
17 All the
adverse events were mild or moderate in severity.
18 Adverse events were more frequent with clindamycin (58 of 265
19 Adverse events were more frequent with tofacitinib than with
20 10 mg (n=296), and placebo (n=260) groups, the most common
adverse events were nasopharyngitis (38 [14%] vs 36 [12%] vs
21 tors to rFIXFc; in the 30 enrolled patients the most common
adverse events were nasopharyngitis (n=7; 23%) and fall (n=6;
22 The most comment grade 3-4
adverse events were neutropenia (n=2 [5%]), hypertension (n=2
23 Adverse events were not assessed.
24 Deaths due to
adverse events were observed in 27 (12%) patients in the pacr
25 Fewer grade 3 and 4 treatment-related
adverse events were observed in patients on nivolumab (14% v
26 Adverse events were rarely reported.
27 Adverse events were recorded at baseline, 3 hours, and 24 hou
28 No severe
adverse events were recorded.
29 Adverse events were reported as expected and were similar bet
30 Serious
adverse events were reported in 102 (25%) of 403 patients in
31 Grade 3 to 4 treatment-related
adverse events were reported in 38.3% and 61.7% of the patien
32 Serious
adverse events were reported in 56 (58%) eltrombopag-treated
33 Serious
adverse events were reported in 64 (22%) of 288 patients in t
34 No grade 3 or 4
adverse events were reported in either study.
35 11 serious
adverse events were reported in seven (25%) patients and incl
36 Three serious
adverse events were reported, all in patients in the adalimum
37 No severe vaccine-related
adverse events were reported.
38 No
adverse events were reported.
39 Most
adverse events were respiratory, and in some patients it led
40 Treatment-related serious
adverse events were similar between groups (13 [11%] in the c
41 Adverse events were similar between the subgroups.
42 Discontinuation due to
adverse events were similar in both arms (6% lapatinib and 5%
43 Adverse events were similar in both groups and uncommon.
44 The rates of renal
adverse events were similar in the liraglutide group and the
45 The most common
adverse events were skin reactions occurring in 49 (48%) of 1
46 Patient characteristics and
adverse events were studied and compared between patients wit
47 Psychiatric
adverse events were the most common in both groups (six [27%]
48 35 or 60 mg/m(2) The most common grade 3 to 4 drug-related
adverse events were thrombocytopenia (47%), neutropenia (32%)
49 The most frequently observed grade 3 and 4
adverse events were transaminase increases (40% alanine amino
50 ion, and worsening of IPF; and the most common grade 3 or 4
adverse events were worsening of IPF, dyspnoea, and pneumonia